About DiagNodus



Latest News

February 2020: Dr Olga Gandelman joins the Board of DiagNodus

January 2019: The multicentre clinical study of the use of DiagNodus approach for CRC detection produces impressive results

May 2018: Sample collection for the multicentre clinical study of the use of DiagNodus approach for CRC detection successfully completed

December 2017: The clinical study of the use of DiagNodus approach for CRC detection made multicentre (Yeovil District Hospital and Southend University Hospital joined the study)



About DiagNodus

Company Summary

DiagNodus Ltd is a medical diagnostics company which is pioneering the development of novel non-invasive methods of biological material collection and testing for colorectal disease detection. Producing patient-friendly highly sensitive diagnostic solutions is the principal goal of the company.

DiagNodus devices will provide simple and reliable tools for diagnosis, monitoring and treatment efficiency assessment in the area of inflammatory bowel disease (IBD). They will also save lives by improving early detection (by non-invasively triaging symptomatic patients) and population screening efficiency for colorectal cancer (CRC).

Short History

DiagNodus was founded in 2011 by a group of scientists with extensive experience in the field of colorectal disease. Their aim was to develop entirely non-invasive methods for diagnosing and monitoring diseases which could be used by patients in their own home.

In 2011 DiagNodus established its laboratory at the Babraham Research Campus in Cambridge, UK.

Between 2012 and 2016 the company organised and successfully completed its first clinical study addressing several important endpoints related to the detection and clinical management of IBD in collaboration with the Department of Gastroenterology of St George's Hospital in London. This study, which was supported by a grant from Innovate UK, has demonstrated excellent acceptance of DiagNodus sampling method by patients and produced highly impressive results on both IBD detection and treatment efficiency assessment by the new approach. Results of the study were published as three peer-reviewed papers. The first patent of DiagNodus was granted in 2016 and the second one in 2018.In 2016 DiagNodus was awarded the Seal of Excellence by the European Commission.

Current Progress

CRC detection constitutes the most important target of DiagNodus, and in 2017-18 the company has undertaken another clinical study (also supported by a grant from Innovate UK). The study included three clinical centres (St George's Hospital, Yeovil District Hospital and Southend University Hospital), and its results have convincingly proven our concept for CRC. The preliminary results of this study have been published in 2019, and the main paper summarising study outcome is now submitted for publication.

Commercial product development has now become the first priority of DiagNodus, and the company continues its efforts on Series A fundraising needed for supporting product development.


Copan Flock Technologies
St George's Healthcare NHS Trust
Medicys Limited
Marks & Clerk LLP




© DiagNodus 2020. All rights reserved. Terms of Use Policy. Privacy Policy
DiagNodus Ltd Registered in England number: 7600875 VAT Number: 121522366
Registered Office: 280 Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT